Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments

doi:10.1016/j.canlet.2017.11.019

CORC > 自动化研究所 > 中国科学院自动化研究所 > 中国科学院分子影像重点实验室

	Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments
	Du, Yang 1,2; Liang, Xiaolong 3; Li, Yuan 1,4; Sun, Ting 1,4; Xue, Huadan 4; Jin, Zhengyu 4; Tian, Jie1,2
刊名	CANCER LETTERS
	2018-02-01
卷号	414 期号:414 页码:230-238
关键词	Programmed Cell Death Ligand-1 Near Infrared Fluorescence Magnetic Resonance Imaging Paclitaxel Chemotherapy Immunotherapy
DOI	10.1016/j.canlet.2017.11.019
文献子类	Article
英文摘要	Programmed death ligand-1 (PD-L1) is a central element in cancer therapies targeting immune checkpoints, and its expression is an important predictor of the therapeutic response. With recent approvals of therapeutic antibodies against PD-L1 and PD-1, noninvasive detection methods are now urgently needed to quantify PD-L1 expression in tumors and to evaluate the response to immune therapies. However, only few such methods are available. Thus, we fabricated nanohybrid liposomal cerasome nanoparticles loaded with the chemotherapeutic drug paclitaxel, and evaluated their value as a theranostic agent. The particles are also decorated with PD-L1 antibody to enable specific targeting, and are dual-labeled to enable near-infrared fluorescence (NIRF) and magnetic resonance imaging (MRI) in vivo. Results showed that in vivo NIRF and MRI imaging following intravenous injection of cerasomes revealed a strong positive contrast for tumors, indicating long-lived enhancement of relevant signals. Moreover, the cerasomes were more effective against tumors and metastasis in comparison to simultaneous but nontargeted delivery of PD-L1 antibody and paclitaxel. Taken together, the data indicate that targeted, dual-labeled cerasomes are good theranostic agents for MRI/NIRF dual-mode detection and treatment of solid tumors in situ. (C) 2017 Elsevier B.V. All rights reserved.
WOS关键词	IMMUNE CHECKPOINT BLOCKADE ; CELL LUNG-CANCER ; THERAPY ; IMMUNOTHERAPY ; CHEMOTHERAPY ; TUMORS ; NANOPARTICLES ; COMBINATION ; EXPRESSION ; STABILITY
WOS研究方向	Oncology
语种	英语
WOS记录号	WOS:000419810900024
资助机构	National Natural Science Foundation of China(81227901 ; Research and Development Program of China (973)(2014CB748600 ; National Key Research and Development Program of China(2017YFA0205200) ; Chinese Academy of Sciences(XDB02060010) ; International Innovation Team of CAS(20140491524) ; Beijing Municipal Science & Technology Commission(Z161100002616022) ; Beijing Natural Science Foundation(Z16110200010000) ; Peking University Third Hospital(BYSY2015023) ; 81470083 ; 2015CB755500) ; 81527805 ; 61231004 ; 81571810 ; 81771846)
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/19586]
专题	自动化研究所_中国科学院分子影像重点实验室
作者单位	1.Chinese Acad Sci, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China 3.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China 4.Beijing Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Du, Yang,Liang, Xiaolong,Li, Yuan,et al. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments[J]. CANCER LETTERS,2018,414(414):230-238.
APA	Du, Yang.,Liang, Xiaolong.,Li, Yuan.,Sun, Ting.,Xue, Huadan.,...&Tian, Jie.(2018).Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.CANCER LETTERS,414(414),230-238.
MLA	Du, Yang,et al."Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments".CANCER LETTERS 414.414(2018):230-238.